CD3xCD117 BTCE

CD3xCD117 BTCE is a bispecific T-cell engager (BTCE) designed to simultaneously bind to CD3, a component of the T-cell receptor complex on T cells, and CD117 (also known as c-Kit), a receptor tyrosine kinase expressed on certain hematopoietic stem and progenitor cells as well as some malignancies. By engaging both targets, this drug redirects cytotoxic T cells toward CD117-expressing malignant or abnormal cells, promoting targeted cell lysis through immune-mediated mechanisms. This approach is part of the broader class of immunotherapies aiming to harness the body's own immune system for cancer treatment. The primary indication under investigation for this agent is likely hematologic malignancies expressing CD117, such as acute myeloid leukemia (AML) or other related disorders.